麻豆传媒

Dr. David Baskin is board certified by the American Board of Neurological Surgery. He completed his medical training at Mount Sinai School of Medicine of the CUNY, and a residency at the University of California. He completed a fellowship in neural protection at the University of Capetown Medical School. He also completed a fellowship in brain endorphins at the University of California. Baskin is the primary investigator for a number of clinical trials looking at different novel diagnostics and treatments for primary brain tumors and autistic spectrum disorder. His clinical focus is on the treatment of brain and spinal tumors.

Steven K. Libutti, MD, FACS, was appointed as Director of Rutgers Cancer Institute of New Jersey and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences in January 2017. In addition to his leadership roles within Rutgers University, Dr. Libutti also serves as Senior Vice President of Oncology Services for RWJBarnabas Health, further strengthening the university鈥檚 partnership with the healthcare system. He is also a Professor of Surgery at Rutgers Robert Wood Johnson Medical School and an Affiliated Distinguished Professor in Genetics at the Rutgers School of Arts and Sciences Department of Genetics.

Most recently, Dr. Libutti served as Director for the Montefiore Einstein Center for Cancer Care in New York City and was a Professor and Vice Chairman of the Department of Surgery and Professor in the Department of Genetics at Albert Einstein College of Medicine and Montefiore Health System. A surgical oncologist, Dr. Libutti is an internationally known expert in endocrine surgery and the management of neuroendocrine tumors. He is the immediate Past President of the American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas.

The recipient of funding from the National Cancer Institute (NCI) for the past 20 years, Dr. Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment and blood vessel formation in tumors. He is studying tumor neovascular formation and the interaction between tumor cells, endothelial cells and the components of the tumor microenvironment including fibroblasts and cancer stem cells. His work also focuses on a better understanding of the tumor suppressor genes MEN1 and FILIP1L.

After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the NCI in surgical oncology and endocrine surgery. He continued at the NCI where he became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch.  He has published over 280 peer reviewed journal articles, is Editor-in-Chief of the Nature Journal Cancer Gene Therapy, and holds seven U.S. patents. 

Clinical Expertise:
Neuroendocrine tumors, thyroid cancer, parathyroid tumors, pancreatic cancer, liver cancer, gastrointestinal (GI) cancers, minimally invasive surgery, and clinical trials.

Debashish Bose, M.D., PhD, FACS, an experienced, well-respected surgeon, serves as Medical Director of The Center for Hepatobiliary Disease at Mercy as well as Associate Director of Surgical Oncology at Mercy in Baltimore, Maryland. He is Board Certified in General Surgery and offers particular expertise in advanced surgical techniques for pancreatic cancer and liver cancer. Dr. Bose provides leading edge cancer treatment options, including minimally invasive and robotic surgery in the care of late-stage and complex oncologic disease. He and his colleagues treat benign and malignant tumors in the peritoneal and abdominal cavity, including: · Stomach and Gastrointestinal Tract Tumors and Cancer · Pancreatic and Neuroendocrine Tumors · Soft Tissue Sarcoma · Metastatic Colon Cancer · Liver Tumors · Adrenal Gland Cancer Dr. Bose works in close collaboration with the liver and pancreatic experts at Mercy’s Institute for Digestive Health and Liver Disease to provide patients the best possible outcome for their diagnosis. Mercy Medical Center’s renowned surgical oncologists teamed with the experience of its liver and pancreatic experts provide patients seeking care for pancreatic cancer one of the most comprehensive gastrointestinal cancer teams in the Mid-Atlantic region. In addition to offering surgical expertise, Dr. Bose aims to provide cancer patients with the knowledge and information needed for them to better understand their specific diagnosis, treatment and outcomes. He has dedicated his career to becoming an ally and a resource for patients facing late-stage and complex cancers. He guides patients through the treatment process and helps them make decisions to optimize their care and regain hope for a better quality of life. Second opinion consultation and collaborative care with partner physicians make Dr. Bose a trusted expert among both patients and colleagues. Gastroenterologists, medical oncologists and primary care physicians rely on Dr. Bose for his insights, surgical skill and commitment to improving cancer survival. Dr. Debashish Bose actively participates in research and has been the recipient of the Ruth L. Kirschstein National Research Service Award (NRSA). He has served as Principle Investigator in studies related to pancreatic cancer. His work has been published in peer-reviewed articles, book chapters and abstracts, and he has made numerous presentations to foster clinical advances in surgical oncology. Education & Fellowships · Fellowship: University of Texas MD Anderson Cancer Center · Residency: Johns Hopkins Hospital · Medical Degree: University of Maryland School of Medicine

I am a gastrointestinal medical oncologist with a research focus on novel clinical trials and cancer immunotherapy. I have gained experience in translational research and clinical trial design through a Master's program in clinical and translational science. My current work involves understanding the biology of gastrointestinal cancers and designing novel clinical trials to improve patient outcomes. Besides, I am interested in studying mechanisms of immune dysfunction in obese cancer patients and the use of immune checkpoint inhibitors in solid tumors. I have led over a dozen clinical trials as a Principal Investigator (PI) and received six grants as a PI or co-investigator. Many of my studies are investigator-initiated and grant-funded through national organizations like the National Cancer Institute (NCI) and the department of defense (DOD). My work has resulted in several national/international presentations and peer-reviewed publications in high-impact journals. As a physician-scientist, my goal is to conduct innovative clinical trials using novel immunotherapy agents and take discoveries from the lab to the bedside to improve life expectancy as well as the quality of life of cancer patients. As an educator, I strive to improve the quality of oncology education and mentor the next generation of clinician investigators.

I have had the opportunity to serve the American Society of Clinical Oncology (ASCO). I have been a member of the Trainee Council Working Group, Clinical Practice Guidelines Committee, and the Professional Development Committee at ASCO. I have also served on multiple guidelines panels for ASCO. Currently, I am a guidelines panel member at the National Comprehensive Cancer Network and at the International Society for Diseases of the Esophagus. 

I have been fortunate to receive many national and international awards. I have been asked to review manuscripts for reputed journals and grant applications for federal funding agencies.

For me, caring for a cancer patient is more than treating a disease; it's a healing process involving both the patient's body, mind, and caregivers. I would like to see myself as a successful clinical and translational researcher and a compassionate physician, and a thought leader in the field of gastrointestinal cancers.

Positions
Roswell Park Comprehensive Cancer
Assistant Professor of Oncology
Assistant Professor of Immunology
Department of Medicine
Co-Leader, GI Translational Research Group
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Assistant Professor
Background
Education and Training:
2010 - MD - Nilratan Sircar Medical College, West Bengal University of Health Sciences, India
2018 - MS - Master of Science in Clinical and Translational Science, University of Oklahoma, Oklahoma City, OK
Residency:
2012-2015 - Saint Joseph Hospital, Chicago, IL
Fellowship:
2015-2018 - University of Oklahoma Health Sciences Center, Oklahoma City, OK
Board Certification:
2018 - Medical Oncology - American Board of Internal Medicine
2018 - Hematology - American Board of Internal Medicine
2015 - Internal Medicine - American Board of Internal Medicine
Professional Memberships:
Society for Immunotherapy of Cancer
American Association for Cancer Research
American College of Gastroenterology
North American Neuroendocrine Tumor Society
European Society of Medical Oncology
American Society of Clinical Oncology
Professional Experience:
2021-present - Quality Subcommittee, Society for Immunotherapy of Cancer (SITC)
2018-present - Board of Directors, Esophageal Cancer Action Network
2017-2018 - Chief fellow, Hematology-Oncology, University of Oklahoma
2017-2018 - Clinical Practice Guidelines Committee, ASCO
2016-2018 - Professional Development Committee, ASCO
Honors & Awards:
Clinical Investigator Scholarship Award, North American Neuroendocrine Tumor Society
ASCO/AACR Methods in Clinical Cancer Workshop, Vail, CO
James N. George award for the outstanding fellow in hematology-oncology, University of Oklahoma
Gold Humanism Honor Society
Conquer Cancer Foundation Merit Award, ASCO
Alpha Omega Alpha (AOA) Honor Medical Society
Early Career Reviewer, Developmental Therapeutics (DT), Center for Scientific Review, National Institutes of Health
Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Network (SCION) Workshop participant
Young Investigator Award, ESMO World Congress on Gastrointestinal Cancer
Clinical Trials
Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma
Learn More
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
Learn More
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Learn M

Steven K. Libutti, MD, FACS was appointed Director of Rutgers Cancer Institute and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences in January 2017. On October 17th, 2024, Dr. Libutti was named the inaugural William N. Hait Director of Rutgers Cancer Institute. In addition to his leadership roles within Rutgers University, Dr. Libutti serves as Senior Vice President of Oncology Services for RWJBarnabas Health. He is also a Distinguished Professor of Surgery at Rutgers Robert Wood Johnson Medical School and an Affiliated Distinguished Professor in Genetics, Rutgers School of Arts and Sciences. 
 
After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the National Cancer Institute (NCI) in surgical oncology. He continued at the NCI where he became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch. Following his time at the NCI, he served as the Director of the Montefiore Einstein Center for Cancer Care and as an Associate Director of the Albert Einstein Cancer Center for eight years prior to joining Rutgers and RWJBarnabas Health.
 
Dr. Libutti is an internationally known expert in the management of neuroendocrine tumors and Past President of the American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas. The recipient of funding from the NCI for the past 25 years, Dr. Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment as well as on a better understanding of the tumor suppressor genes MEN1 and FILIP1L. He has published over 300 peer reviewed journal articles, is Editor-in-Chief Emeritus of the Springer-Nature Journal Cancer Gene Therapy and holds eleven U.S. patents. Dr. Libutti has successfully navigated Rutgers Cancer Institute’s P30 CCSG Comprehensive Cancer Center Award through two competitive renewals, the most recent of which in 2023 achieved the Center’s highest score to date placing it among the top centers in the US.